CRIS Current Research Information System

MARTINELLI, GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 31.244
EU - Europa 24.354
AS - Asia 12.477
AF - Africa 1.638
SA - Sud America 88
Continente sconosciuto - Info sul continente non disponibili 70
OC - Oceania 39
Totale 69.910
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 31.107
GB - Regno Unito 7.854
CN - Cina 4.137
VN - Vietnam 4.040
SE - Svezia 3.994
IT - Italia 3.560
DE - Germania 2.983
SG - Singapore 1.911
IN - India 1.429
IE - Irlanda 1.007
UA - Ucraina 997
FR - Francia 969
RU - Federazione Russa 857
ZA - Sudafrica 575
TG - Togo 553
EE - Estonia 548
CH - Svizzera 398
BG - Bulgaria 295
JO - Giordania 256
CI - Costa d'Avorio 229
JP - Giappone 198
FI - Finlandia 191
NG - Nigeria 189
GR - Grecia 183
BE - Belgio 167
IR - Iran 139
CA - Canada 129
SC - Seychelles 77
NL - Olanda 70
EU - Europa 65
TR - Turchia 61
AT - Austria 52
KR - Corea 52
HR - Croazia 45
HK - Hong Kong 42
UZ - Uzbekistan 42
LB - Libano 41
BR - Brasile 40
PL - Polonia 37
AU - Australia 30
CL - Cile 29
ES - Italia 27
PH - Filippine 26
CZ - Repubblica Ceca 23
RO - Romania 23
MY - Malesia 16
PT - Portogallo 12
SA - Arabia Saudita 11
TW - Taiwan 11
ID - Indonesia 10
RS - Serbia 10
NO - Norvegia 9
NZ - Nuova Zelanda 9
EG - Egitto 8
PE - Perù 8
BD - Bangladesh 7
IL - Israele 7
AE - Emirati Arabi Uniti 6
DK - Danimarca 6
MK - Macedonia 6
A2 - ???statistics.table.value.countryCode.A2??? 5
KZ - Kazakistan 5
LT - Lituania 5
PK - Pakistan 5
SK - Slovacchia (Repubblica Slovacca) 5
EC - Ecuador 4
HU - Ungheria 4
KG - Kirghizistan 4
LU - Lussemburgo 4
MX - Messico 4
QA - Qatar 4
AR - Argentina 3
BA - Bosnia-Erzegovina 3
IQ - Iraq 3
KW - Kuwait 3
LA - Repubblica Popolare Democratica del Laos 3
LV - Lettonia 3
MA - Marocco 3
AL - Albania 2
AM - Armenia 2
MD - Moldavia 2
PA - Panama 2
TM - Turkmenistan 2
AZ - Azerbaigian 1
BO - Bolivia 1
BS - Bahamas 1
CO - Colombia 1
ET - Etiopia 1
GE - Georgia 1
HN - Honduras 1
KE - Kenya 1
LI - Liechtenstein 1
LK - Sri Lanka 1
MC - Monaco 1
ML - Mali 1
SI - Slovenia 1
SY - Repubblica araba siriana 1
UG - Uganda 1
UY - Uruguay 1
VE - Venezuela 1
Totale 69.910
Salva come PNG Salva come JPEG
Città #
Southend 7.305
Fairfield 4.103
Chandler 3.290
Dong Ket 2.581
Ashburn 2.449
Woodbridge 2.048
Houston 2.033
Wilmington 1.888
Seattle 1.804
Ann Arbor 1.622
Singapore 1.603
Princeton 1.431
Cambridge 1.413
Dublin 1.001
Nanjing 656
Westminster 651
Padova 621
Bologna 596
Lomé 553
Beijing 510
Jacksonville 499
Berlin 352
Santa Clara 338
Bern 336
Jinan 321
Saint Petersburg 321
New York 309
Shenyang 306
Medford 289
Sofia 287
Amman 256
Hebei 246
San Diego 236
Milan 231
Abidjan 229
Turin 226
Nanchang 217
Changsha 207
Boardman 202
Bremen 201
Abeokuta 188
Helsinki 180
Redmond 178
Brussels 161
Jiaxing 148
Tokyo 146
Florence 144
Tianjin 144
Falls Church 138
Redwood City 138
Mülheim 125
Norwalk 110
Los Angeles 95
Zhengzhou 95
Guangzhou 93
Haikou 93
Hangzhou 89
Rome 87
Taizhou 84
Ningbo 82
Dearborn 78
Mountain View 72
Mahé 71
Toronto 69
Des Moines 66
Bühl 60
Olalla 60
Shanghai 58
Paris 51
Taiyuan 51
Hyderabad 50
Lanzhou 50
Frankfurt am Main 46
Verona 46
Kunming 45
London 44
Forlì 43
Istanbul 43
Phoenix 38
Andover 37
Athens 36
Fuzhou 36
Leawood 34
Washington 34
Vienna 32
Fremont 31
Zanjan 31
Hong Kong 26
Tappahannock 26
Pune 25
São Paulo 25
Amsterdam 24
Grafing 24
North York 24
San Francisco 24
Davao City 23
Frankfurt Am Main 23
Lausanne 22
Tehran 22
Chicago 21
Totale 47.906
Salva come PNG Salva come JPEG
Nome #
Instillazione diretta intranasale di amfotericina B liposomiale nella terapia delle micosi nasali. 491
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia 326
Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery 278
Application of the whole-transcriptome shotgun sequencing approach to the study of Philadelphia-positive acute lymphoblastic leukemia 271
A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia 249
A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium 232
Adult "Triple Negative" ACUTE Lymphoblastic Leukemia Genome Wide Characterization 227
A POLYMORPHISM IN THE CHROMOSOME 9P21 ANRIL LOCUS IS ASSOCIATED TO PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA SUSCEPTIBILITY 226
B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. 221
A NEW SUBSET OF ADULT B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENT WITH PREDNISONE-INDUCED MONOCYTIC DIFFERENTIATION? 218
Aggressive Aneuploid Acute Myeloid Leukemia Is Dependent on Alterations of P53, Gain of APC and PLK1 and Loss of RAD50 213
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia 213
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. 213
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 212
14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia 204
5′UTR point substitutions and N-terminal truncating mutations of ANKRD26 in acute myeloid leukemia 199
Prolonged low-dose azacitidine schedule in high-risk MDS patients: Hematologic and molecular response 198
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis 197
A HIGH SENSITIVE NANOFLUIDIC ARRAY IMPROVES THE DETECTION OF RARE COPIES OF BCR-ABL1 TRANSCRIPT IN PATIENTS WITH PHILADELPHIA POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 196
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies 195
A calpain-cleaved fragment of β-catenin promotes BCRABL1+ cell survival evoked by autophagy induction in response to imatinib 193
Alterations in phosphatidylinositol 3-phosphate (PI3P) pathway and cAMP pathway confirm poor prognosis and reduced overall survival (OS) in a series of 209 acute myeloid leukemia patients 192
Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy 191
Chromothripsis in acute myeloid leukemia: Biological features and impact on survival 190
c-MYC oncoprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in Chronic Myelogenous Leukemia CD34+ hematopoietic progenitor cells 189
Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients 188
CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients. 187
Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience 185
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 183
Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies 178
Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient. 176
The alteration in key regulator genes of autophagy is mainstream mechanism of therapy resistance and impact prognosis of acute myelogenous leukemia (AML): results from diagnosis genomic analysis on 148 consecutive patients treated with intensive chemotherapy and long-term survival follow-up 176
Cauliflower Mosaic Virus TAV, a Plant Virus Protein That Functions like Ribonuclease H1 and is Cytotoxic to Glioma Cells 175
A novel t(2;10)(q31;p12) balanced translocation in acute myeloid leukemia 172
BCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemia. 172
Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia. 171
Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations 171
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia 169
A case report of acute myeloid leukemia and neurofibromatosis 1 169
Alterations of BRCA1 and PALB2 Define a Novel Class of Complex-Karyotype AML with a Very Bad Prognosis 168
Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by gene expression profiling (gep) 167
Advances in the treatment for haematological malignancies. 167
Co-occurrence of alterations in the DNA damage repair genes synergize with uncontrolled proliferation and associate with very-poor prognosis in acute myeloid leukemia patients 165
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia 164
Assessment of the interlaboratory variability and robustness of JAK2V617Fmutation assays: A study involving a consortium of 19 Italian laboratories 164
Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia. 162
Denaturing-HPLC-based assay for detection of ABL mutations in Chronic Myeloid Leukemia patients resistant to Imatinib 161
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. 161
Comparison of JAK2V617F-positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology 161
Chibby 1: A new component of β-catenin-signaling in chronic myeloid leukemia 161
14-3-3 ligand prevents nuclear import of c-ABL protein in chronic myeloid leukemia 160
ARF Loss, a Negative Prognostic Factor in Philadelphia-Positive Acute Lymphoblastic Leukemia, May Be Efficiently Overcome by the Small Molecule MDM2 Antagonist RG7112 160
Chromothripsis in AML patients: A new mechanism of cancer initiation and progression 160
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 160
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 159
First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. 158
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. 158
Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas 157
BCR-ABL1 transcript detection in patients with Philadelphia-positive Acute Lymphoblastic Leukemia (ALL) using a new and high sensitive nanofluidic method 156
c-Abl and Src-family kinases cross-talk in regulation of myeloid cell migration 155
Chibby drives β catenin cytoplasmic accumulation leading to activation of the unfolded protein response in BCR-ABL1+ cells 155
Acetylation of FOXO3a transcription factor in response to imatinib of chronic myeloid leukemia 155
A cell cycle-related genomic and transcriptomic signature distinguish aneuploid and euploid acute myeloid leukemia 155
CLINICAL OUTCOMES PREDICTION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE-DEXAMETHASONE AND AUTOLOGOUS STEM CELL TRANSPLANTATION BY 8-GENE SIGNATURE OF CD138+ PLASMA CELLS 154
Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Patients with Coronary Artery Disease and in Centenarians. Further Clues Linking Chip with Cardiovascular Risk 154
Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr–Abl mutations and mutational analysis 153
Clonal activation of Akt in low-risk MDS patients with del(5q) treated with lenalidomide 153
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD) 153
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 153
Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role ofMPLpolymorphisms 153
No preferential sensitivity of t(8;21) acute myeloid leukemias to cytosine arabinoside in vitro: is intensity of therapy or high dose Ara-C crucial for response? 152
Bellerophontes: an RNA-Seq data analysis framework for chimeric transcripts discovery based on accurate fusion model 152
The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report 151
Clustering Adult ACUTE Lymphoblastic Leukemia (ALL) Philadelphia Negative (Ph-) By Whole Exome Sequencing (WES) Analysis 151
Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia 150
Gene expression profiling of normal and malignant CD34-derived megakaryocytic cells. 149
AZACITIDINE IN MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF LONG-RESPONDER PATIENTS 149
Acute promyelocytic leukemia with amplification of PML-RARalpha rearrangement:clinical implications 149
ACTIVATION-INDUCED CYTIDINE DEAMINASE IS ABERRANTLY OVEREXPRESSED IN BCRABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA CELLS AND PROMOTES DNA-SINGLE STRAND BREAKS 148
CHK2 drives late G1/early S phase arrest of clonal myeloid progenitors expressing the p210 BCR-ABL tyrosine kinase in response to STI571 148
Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. 146
Optimized pipeline of MuTect and GATK tools to improve the detection of somatic single nucleotide polymorphisms in whole-exome sequencing data 146
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis 145
Bromodomain Inhibition Is Effective Against Acute Myeloid Leukemia Cells Under Hypoxia and Induces Genome-Dependent Metabolic Perturbations 144
Complete hematologic and molecular response in adult patients with relapsed/refractory philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: Results from a phase II, single-arm, multicenter study 144
AZACITIDINE IN HIGH AND LOW RISK MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF 57 PATIENTS TREATED WITH 4 DIFFERENT THERAPEUTIC REGIMENS 143
Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities 143
AZACITIDINE FOR HIGH RISK MYELODYSPLASTIC SYNDROMES. RETROSPECTIVE EVALUATION OF TWO DIFFERENT DOSING SCHEDULES 142
A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia. 141
Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes 141
AICDA expression in BCR/ABL1-positive acute lymphoblastic leukaemia is associated with a peculiar gene expression profile. 140
A multicenter phase II trial (SAKK 36/06) of single-agent Everolimus(RAD001) in patients with relapsed or refractory mantle cell lymphoma. 140
Epigenetically induced ectopic expression of uncx impairs the proliferation and differentiation of myeloid cells 140
First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 140
BCR-ABL1-Positive Acute Lymphoblastic Leukemia Patients Treated with Only TKI Vs Conventional Chemo Plus TKI Therapy Show Similar DNA Alterations At Relapse Targeting Key Regulators of Tumor Suppression, Cell Cycle Control, and Lymphoid/B-Cell Development 140
CIRCULATING CD34+ STEM/PROGENITOR CELLS FROM TRIPLE NEGATIVE PATIENTS WITH MYELOFIBROSIS SHOW DIFFERENT NUMBER, GENE EXPRESSION PROFILE AND IN VITRO RESPONSE TO INFLAMMATORY STIMULI AS COMPARED WITH THE JAK2(V617F) MUTATED COUNTERPARTS 140
AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications. 139
Network integration of multi-tumour omics data suggests novel targeting strategies 139
Accuracy of Mobile Applications versus Wearable Devices in Long-Term Step Measurements 139
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia 139
Totale 17.458
Salva come PNG Salva come JPEG
Categoria #
all - tutte 175.493
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 175.493
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202015.039 0 0 122 1.234 1.869 1.802 2.172 2.145 2.529 1.164 869 1.133
2020/202110.786 1.826 619 199 306 271 451 243 604 999 489 521 4.258
2021/202213.288 1.535 364 875 1.149 1.272 869 288 883 603 982 2.280 2.188
2022/202314.358 1.686 2.270 759 1.884 945 1.088 505 775 2.257 322 1.167 700
2023/20244.044 222 612 227 377 296 884 269 302 173 249 216 217
2024/20253.945 547 2.291 1.107 0 0 0 0 0 0 0 0 0
Totale 71.717